Akero Therapeutics Inc. (AKRO) receives a Buy rating from UBS


Akero Therapeutics Inc.’s filing revealed that its Director Graham G. Walmsley acquired Company’s shares for reported $10.4 million on Sep 19. In the deal valued at $26.00 per share,400,000 shares were bought. As a result of this transaction, Graham G. Walmsley now holds 400,000 shares worth roughly $ 19.9 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Yale Catriona sold 5,745 shares, generating $287,191 in total proceeds. Upon selling the shares at $49.99, the Chief Development Officer now owns 46,627 shares.

Before that, Graham G. Walmsley bought 25,000 shares. Akero Therapeutics Inc. shares valued at $1,051,475 were divested by the Director at a price of $42.06 per share. As a result of the transaction, Graham G. Walmsley now holds 600,000 shares, worth roughly $29.84 million.

UBS initiated its Akero Therapeutics Inc. [AKRO] rating to a Buy in a research note published on Friday, August 28, 2023; the price target was $83. PT values the company’s stock at a premium of 40.07 to its Friday closing price.

Price Performance Review of AKRO

On Friday, Akero Therapeutics Inc. [NASDAQ:AKRO] saw its stock jump 0.22% to $49.74. On the same session, the stock had its day’s lowest price of $49.19, but rose to a high of $50.24. Over the last five days, the stock has gained 3.69%. Akero Therapeutics Inc. shares have fallen nearly -9.23% since the year began. Nevertheless, the stocks have risen 323.32% over the past one year. While a 52-week high of $58.38 was reached on 06/13/23, a 52-week low of $10.48 was recorded on 03/22/23. SMA at 50 days reached $45.57, while 200 days put it at $45.30. A total of 0.78 million shares were traded, compared to the trading of 0.52 million shares in the previous session.

Levels Of Support And Resistance For AKRO Stock

The 24-hour chart illustrates a support level at 49.21, which if violated will result in even more drops to 48.67. On the upside, there is a resistance level at 50.26. A further resistance level may holdings at 50.77. The Relative Strength Index (RSI) on the 14-day chart is 64.14, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.66, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 28.89%. Stochastics %K at 70.45% indicates the stock is a holding.

How much short interest is there in Akero Therapeutics Inc.?

A steep rise in short interest was recorded in Akero Therapeutics Inc. stocks on Aug 14, 2023, growing by 0.38 million shares to a total of 5.86 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 5.48 million shares. There was a rise of 6.48%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 10.82% of the overall stock float, the days-to-cover ratio (short ratio) rose to 11.11.

Akero Therapeutics Inc. [AKRO] – Who Are The Largest Shareholders?

In filings from Janus Henderson Investors US LLC, it is revealed that the company now owns 4,403,909 shares, or roughly 7.92% of the outstanding AKRO shares. In other words, the investor’s shares have risen by 604,743 from its previous 13-F filing of 3799166.0. Additionally, Alkeon Capital Management LLC increased 7.66% of its stake after which the total value it holdings stand at $150,484,292, while T. Rowe Price Associates, Inc. added 24.79% of its stake to hold $141.01 million in the firm. Over the last quarter, Adage Capital Management LP purchased 658,986 shares of Akero Therapeutics Inc., while BlackRock Fund Advisors bought 478,974 shares. At present, The Vanguard Group, Inc. is holding 2,560,827 shares valued at $111.14 million. Baker Bros. Advisors LP owned 2,368,378 shares of the company at the time of its most recent 13F filing, worth $102.79 million.

According to FactSet, Akero Therapeutics Inc.’s share price will average $62.88 in the next year, based on opinions of analysts polled by the firm. This is up nearly 24.92 percent from its previous closing price of $49.63. Analysts expect Akero Therapeutics Inc. stock to reach the higher price of $83.00, while the lowest price estimate is $49.00. However, 8 analysts have rated AKRO stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here